Skip to content

Prevalence of Sleep Apnea/Hypopnea Syndrome in Obese Children

Prevalence of Sleep Apnea/Hypopnea Syndrome in Obese Children. The Significance of Hormonal Factors

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01322763
Acronym
NANOS
Enrollment
200
Registered
2011-03-25
Start date
2008-03-31
Completion date
2012-01-31
Last updated
2011-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Obesity, Sleep Apnea

Brief summary

Principal aim: To determine the prevalence of Sleep Apnea- Hypopnea syndrome in obese children. Secondary aim: 1. To fix the implication of the adenotonsillar hypertrophy, the obesity and the hormonal factors in the pathogeny of SAHS in children. 2. To determinate of clinical and neurophysiologic characteristics of childhood SAHS associated with obesity. DESIGN: A prospective transversal study.

Detailed description

The population of study will be make for children of both sex, between 3 and 14 years old and with body mass index (BMI) ≥ 95 percentile and with informed consent. METHODS: In all children included in the study, the investigators will carry out: previous history, history of snoring and Chervin´s screening questionnaire of SAHS, general physical and otorhinolaryngologic examination with nasopharyngoscopy, blood test with determination of glucose, lipids, insulin, leptin, adiponectin, and ghrelin, polysomnography (PSG) with transcutaneous CO2. The diagnosis of SAHS will be made if on PSG the Respiratory disturbance Index (RDI) is ≥ 3 and/or obstructive hypoventilation is present.

Interventions

None listed

Sponsors

Sociedad Española de Neumología y Cirugía Torácica
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

* Children of both sex, between 3 and 14 years old * Body mass index (BMI) ≥ 95 percentile * With informed consent.

Exclusion criteria

* Without informed consent

Countries

Spain

Contacts

Primary ContactMaría Luz Alonso Alvarez, MD
mlalonso@hgy.es34610246473

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026